Kfar-Sava, Israel Clinical Trials

A listing of Kfar-Sava, Israel clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 45 clinical trials
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

To characterize safety and tolerability and identify a recommended dose and regimen for the LXH254 in combination with LTT462 or trametinib or ribociclib.

KRAS
melanoma skin
BRAF
combinations
trametinib
Novartis Investigative Site
 (9.2 away) Contact site
  • 272 views
  • 05 Jul, 2021
  • +35 other locations
Phase I Pharmacokinetics and Safety Study of Naloxegol in Paediatric OIC Patients

To characterize the pharmacokinetics (PK) of naloxegol after single oral dose and through population PK in paediatric patients with opioid induced constipation (OIC) or at risk of OIC.

Schneider Children Medical Center
 (6.6 away) Contact site
  • 507 views
  • 27 Jan, 2021
  • +26 other locations
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

The purpose of this study is to characterize safety and to determine the putative recommended Phase 2 dose(s) (RP2D[s]) and optimal dosing schedule(s) of JNJ-75348780 in participants with relapsed/ refractory B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) in Part A and to further characterize the safety at the …

measurable disease
cell transplantation
lymphoma
mantle cell lymphoma
high dose chemotherapy
Sheba Medical Center
 (9.0 away) Contact site
  • 0 views
  • 30 Jul, 2021
  • +34 other locations
A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) and maximum tolerated dose (MTD) of JNJ-70218902 in Part 1, and to determine the safety of JNJ-70218902 RP2D(s) in Part 2.

adenocarcinoma
targeted therapy
primary cancer
solid neoplasm
Sourasky Medical Center
 (9.7 away) Contact site
  • 17 views
  • 04 Mar, 2021
  • +9 other locations
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal Gastroesophageal and Renal Cancers

This study will determine the pharmacodynamically-active dose of gevokizumab and the tolerable dose and preliminary efficacy of gevokizumab in combination with the standard of care anti-cancer therapy in patients with metastatic colorectal cancer, metastatic gastroesophageal cancer and metastatic renal cell carcinoma.

measurable disease
cabozantinib
fluoropyrimidine
fluorouracil
metastatic renal cell carcinoma
Novartis Investigative Site
 (9.7 away) Contact site
  • 74 views
  • 02 Jun, 2021
  • +46 other locations
A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors

An open-label, dose-escalation (Part 1), dose-expansion (Part 2) study to assess the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-155 alone and in combination with paclitaxel or docetaxel. In Part 1 (dose escalation), participants will receive escalating doses of ABBV-155 monotherapy (Part 1a) or ABBV-155 in combination with paclitaxel or …

Sheba Medical Center /ID# 230812
 (9.0 away) Contact site
  • 542 views
  • 21 Jun, 2021
  • +45 other locations
Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

This study has dose escalation (Part A, B, C) and dose expansion (Cohorts A-L) parts. Dose escalation is to evaluate the safety, tolerability, and preliminary efficacy of MK-4830 monotherapy administration (Parts A and B) and in combination with pembrolizumab (Part C). Dose expansion is to evaluate the objective response rate …

measurable disease
cetuximab
HER2
primary cancer
carcinoma
Rabin Medical Center ( Site 0043)
 (6.6 away) Contact site
  • 86 views
  • 02 Aug, 2021
  • +27 other locations
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to identify the recommended Phase 2 regimen(s) (RP2R[s]) and schedule for the study treatment (Part 1) and to characterize the safety of the RP2R(s) for the study treatment (Part 2). The RP2R will describe the combination doses and schedules of talquetamab and teclistamab to …

carfilzomib
human chorionic gonadotropin
bortezomib
refractory multiple myeloma
lenalidomide
Sheba Medical Center
 (9.0 away) Contact site
  • 0 views
  • 30 May, 2021
  • +12 other locations
A Study Investigate the Safety Tolerability Pharmacokinetic and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome

This study will investigate the safety and tolerability of SLN124 in patients with Thalassaemia or patients with Very Low- and Low-risk Myelodysplastic Syndrome after single ascending s.c. doses and multiple doses in healthy male and female subjects. Up to 7 cohorts of 56 patients with Thalassaemia and up to 7 …

Israel
 (9.0 away) Contact site
  • 0 views
  • 22 Mar, 2021
  • +13 other locations
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to evaluate the safety and efficacy …

measurable disease
epidermal growth factor
growth factor
osimertinib
epidermal growth factor receptor
Sheba Medical Center /ID# 225585
 (9.0 away) Contact site
  • 0 views
  • 01 Aug, 2021
  • +26 other locations